Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Beta Bionics
Irvine, California, United Statesbetabionics.com ↗
- Ownership
- Public · BBNX
- Employees
- ~291
- Development stage
- Commercial
01
Overview
Beta Bionics has commercialized the iLet Bionic Pancreas for people aged six and up with type 1 diabetes. The system was FDA-cleared in May 2023. Since launch, quarterly revenues have grown from $3.1M to $16.7M as of late 2024/early 2025. The company plans further studies and regulatory submissions to expand use into type 2 diabetes.
- Therapeutic areas
- Endocrinology
- Modalities
- DeviceBiologicSmall molecule
- Industry
- Physiological Monitoring
02
Partnerships
DexcomAbbott
03
Financials
- Market cap
- $706.3M
- Total revenue
- $100.3M
- Enterprise value
- $472.2M
Beyond the preview
Go deeper on Beta Bionics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beta Bionics.